Looking beyond COVID-19 vaccine phase 3 trials
JH Kim, F Marks, JD Clemens - Nature medicine, 2021 - nature.com
After the recent announcement of COVID-19 vaccine efficacy in clinical trials by several
manufacturers for protection against severe disease, a comprehensive post-efficacy strategy …
manufacturers for protection against severe disease, a comprehensive post-efficacy strategy …
[HTML][HTML] Hepatitis B virus infection and hepatocellular carcinoma in sub-Saharan Africa: Implications for elimination of viral hepatitis by 2030?
E Amponsah-Dacosta - World journal of gastroenterology, 2021 - ncbi.nlm.nih.gov
Elimination of viral hepatitis in sub-Saharan Africa by 2030 is an ambitious feat. However, as
stated by the World Health Organization, there are unprecedented opportunities to act and …
stated by the World Health Organization, there are unprecedented opportunities to act and …
[HTML][HTML] The impact of the timely birth dose vaccine on the global elimination of hepatitis B
MJ de Villiers, S Nayagam, TB Hallett - Nature communications, 2021 - nature.com
Abstract In 2016 the World Health Organization set the goal of eliminating hepatitis B
globally by 2030. Horizontal transmission has been greatly reduced in most countries by …
globally by 2030. Horizontal transmission has been greatly reduced in most countries by …
Levels of hepatitis B antibody titers are affected by age and doses gap time in children from a high endemic area of the western Amazon
Background Despite completion of the vaccine schedule for hepatitis B virus (HBV), children
may display levels of HBV surface antibodies (anti-HBs) that are considered inadequate for …
may display levels of HBV surface antibodies (anti-HBs) that are considered inadequate for …
Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NéoVac Study)
A Gosset, MY Diallo, E Betsem, L Schaeffer, N Meda… - Vaccine, 2021 - Elsevier
Abstract Background The World Health Organization (WHO) recommends a first hepatitis B
vaccine dose within 24 h of birth (HepB-BD) to prevent mother-to-child transmission …
vaccine dose within 24 h of birth (HepB-BD) to prevent mother-to-child transmission …
[HTML][HTML] Association of routine hepatitis B vaccination and other effective factors with hepatitis B virus infection: 25 years since the introduction of national hepatitis B …
Background: One of the main health problems in the world is hepatitis B virus (HBV)
infection. Vaccination and other factors can affect HBV infection. As various effective factors …
infection. Vaccination and other factors can affect HBV infection. As various effective factors …
Significance of parenteral viral hepatitis laboratory diagnostics in the Republic of Guinea
S Boumbaly, EN Serikova, AV Semenov… - Journal of …, 2021 - microbiol.crie.ru
Abstract Rationale. Countries of Africa, especially countries in sub-Saharan Africa, represent
a region characterized by high incidence of chronic hepatitis B virus (HBV) and hepatitis C …
a region characterized by high incidence of chronic hepatitis B virus (HBV) and hepatitis C …
[HTML][HTML] Значимость лабораторной диагностики парентеральных вирусных гепатитов в Гвинейской Республике
С Бумбали, ЕН Серикова, АВ Семенов… - Журнал …, 2021 - cyberleninka.ru
Актуальность. Cтраны Африки, особенно к югу от Сахары, являются регионом с
высокими показателями заболеваемости хроническими вирусными гепатитами В (ВГВ) …
высокими показателями заболеваемости хроническими вирусными гепатитами В (ВГВ) …
Vaccination contre le virus de l'hépatite B et prévention du cancer du foie
F Lebossé, F Zoulim - Bulletin du Cancer, 2021 - Elsevier
Résumé Le virus de l'hépatite B (VHB) est un virus fortement oncogène: ses caractéristiques
virologiques propres, les épisodes d'intégration accidentelle d'ADN viral dans le génome de …
virologiques propres, les épisodes d'intégration accidentelle d'ADN viral dans le génome de …
Hepatitis B vaccines
JW Ward - Hepatitis B Virus and Liver Disease, 2021 - Springer
Since 1982, safe and effective hepatitis B virus (HBV) vaccines have been commercially
available first derived from plasma of HBV-infected persons and later from yeast cells using …
available first derived from plasma of HBV-infected persons and later from yeast cells using …